首頁 > 市場調查報告書 > 製藥

婦科治療

市場調查報告書

商品編碼

1479104

纖維囊性乳房疾病市場：現況分析與預測（2023-2030）

Fibrocystic Breast Condition Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年04月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計 2023 年至 2030 年，纖維囊性乳房疾病市場的複合年增長率約為 5.2%。纖維囊性乳房疾病，也稱為纖維囊性變化或纖維囊性乳房，是一種以乳房腫塊為特徵的非癌性疾病。這種情況受到卵巢分泌的荷爾蒙水平波動的影響。雖然很痛苦，但主要影響30歲至50歲的女性，並持續到更年期和更年期。纖維囊性乳房疾病會增加乳癌的風險。乳癌發生率的增加是促使市場擴張的重要驅動因素。例如，據世界衛生組織稱，2022年全球將有約230萬名女性被診斷出罹患乳癌，其中67萬人將死亡。此外，女性對乳房健康和纖維囊性變化盛行率的認識提高可能會促使更多的人尋求醫療評估和治療。此外，乳房X光攝影、超音波和MRI等乳房影像技術的進步有助於纖維囊性乳房疾病的早期發現和準確診斷。

根據診斷，市場分為乳房X光檢查、超音波、臨床乳房檢查等。預計臨床乳房檢查類別在預測期內將佔據最高佔有率。臨床乳房檢查可以由醫療保健提供者在各種環境中進行，包括初級保健診所、婦女健康中心和社區健康活動，使更廣泛的人群更容易獲得這些檢查。醫療保健提供者和組織致力於改進培訓計劃，以提高臨床醫生進行徹底、準確的臨床乳房檢查的熟練程度。這包括正確技術的教育、研究結果的解釋以及與患者的溝通。

依治療方式，纖維囊性乳房疾病市場分為藥物、口服避孕藥、細針抽吸等。藥物可以幫助緩解與纖維囊性乳房疾病相關的症狀，例如乳房疼痛、壓痛和腫脹。非類固醇類抗發炎藥 (NSAID)，例如布洛芬和□普生，通常用於減輕疼痛和發炎。正在進行的臨床試驗正在評估治療纖維囊性乳房疾病的新藥物和治療方法的安全性和有效性。這些研究正在探索新的藥物配方、標靶治療和個人化治療策略，以改善患者的治療結果。

根據最終用戶，纖維囊性乳房疾病市場分為醫院、診所等。其中，預計在預測期內，醫院類別對纖維囊性乳房疾病的採用將會增加。醫院為纖維囊性乳房疾病患者提供全面的醫療服務，包括診斷評估、治療、手術介入和術後護理。醫院提供的多學科方法使患者能夠接受各種醫療保健專業人員（包括內科醫生、外科醫生、放射科醫生、病理學家和護士）的全面協調護理。醫院通常設有專門的乳房中心或診所，並配備了診斷和治療乳房疾病（包括纖維囊性乳房疾病）的專家的醫療專業人員。

為了更瞭解纖維囊性乳房疾病產業的市場實施情況，市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞洲太平洋地區（中國、日本、印度、亞太其他地區）和世界其他國家。北美纖維囊性乳房疾病市場的推動因素包括乳癌盛行率不斷上升、醫療保健專業人員和一般大眾對纖維囊性乳房疾病的認識不斷提高、先進技術的市場發展以及治療選擇的數量預計將繼續增長。例如，根據 CDC 的數據，2019 年估計有 287,500 例女性新診斷出侵襲性乳癌病例。

市場上的一些主要參與者包括Pfizer Inc, AstraZeneca, DMS Group, Bayer AG, Siemens Healthcare Private Limited, Hologic, Inc., FUJIFILM Healthcare, Allengers, BMI Biomedical International, GE HealthCare.。

北美纖維囊性乳房疾病市場
- 美國
- 加拿大
- 其他北美
歐洲纖維囊性乳房疾病市場
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區纖維囊性乳房疾病市場
- 中國
- 日本
- 印度
- 亞太其他地區
其他地區纖維囊性乳房疾病市場

第十一章纖維囊性乳房疾病市場動態

市場驅動力
市場課題
影響分析

第十二章纖維囊性乳房疾病市場機會

第十三章纖維囊性乳房疾病市場趨勢與見解

第十四章供需分析

需求面分析
供給側分析

第十五章價值鏈分析

第16章價格分析

第17章競爭場景

競爭格局
- 波特五力分析

第十八章公司簡介

Pfizer Inc
AstraZeneca
DMS Group
Bayer AG
Siemens Healthcare Private Limited
Hologic, Inc.
FUJIFILM Healthcare
Allengers
BMI Biomedical International
GE HealthCare

第19章免責聲明

簡介目錄

Product Code: UMHE212713

The Fibrocystic breast condition market is expected to register a CAGR of approx. 5.2% over the period of 2023-2030. Fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition characterized by lumpiness in the breasts. The condition is influenced by fluctuating hormone levels produced by the ovaries. Although distressing, it primarily affects women in their 30s and 50s and persists through menopause and perimenopause. The presence of fibrocystic breast disease increases the risk of breast cancer. The increasing occurrence of breast cancer will serve as a significant driver, leading to the expansion of the market. For instance, According to the WHO, Globally, there were approximately 2.3 million women diagnosed with breast cancer in 2022, resulting in 670,000 deaths. Furthermore, greater awareness among women about breast health and the prevalence of fibrocystic changes can lead to more individuals seeking medical evaluation and treatment. Additionally, Technological advancements in breast imaging techniques such as mammography, ultrasound, and MRI contribute to early detection and accurate diagnosis of fibrocystic breast disease.

Based on Diagnosis, the market is segmented into mammogram, ultrasound, clinical breast exam, other. The clinical breast exam category is expected to witness the highest share during the forecast period. Clinical breast exams can be conducted by healthcare providers in various settings, including primary care clinics, women's health centers, and community health events, making them more accessible to a broader population. Healthcare providers and organizations have been focusing on improving training programs for clinicians to enhance their proficiency in conducting thorough and accurate clinical breast exams. This includes providing education on proper technique, interpretation of findings, and communication with patients.

Based on Treatment, the fibrocystic breast condition market has been classified as medication, oral contraceptives, fine-needle aspiration, others. Among them, the myocardial infarction segment is expected to grow at a higher share in the market. Medications can help alleviate symptoms associated with fibrocystic breast disease, such as breast pain, tenderness, and swelling. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, are commonly used to reduce pain and inflammation. Ongoing clinical trials are evaluating the safety and efficacy of novel medications and therapeutic approaches for the treatment of fibrocystic breast disease. These studies explore new drug formulations, targeted therapies, and personalized treatment strategies to improve patient outcomes..

Based on the End-User, the Fibrocystic Breast Condition market has been classified into hospital, clinic, others. Among them, the hospitals category is to witness higher adoption of Fibrocystic Breast Condition during the forecast period. Hospitals provide comprehensive medical services, including diagnostic evaluations, medical treatments, surgical interventions, and post-operative care, for individuals with fibrocystic breast disease. The multi-disciplinary approach offered by hospitals ensures that patients receive integrated and coordinated care from various healthcare professionals, such as physicians, surgeons, radiologists, pathologists, and nurses. Hospitals often have specialized breast health centers or clinics staffed with healthcare providers who have expertise in diagnosing and treating breast conditions, including fibrocystic breast disease.

For a better understanding of the market adoption of the Fibrocystic breast condition industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America Fibrocystic Breast Condition market is expected to continue to grow in the coming years, driven by the increasing prevalence of breast cancer and growing awareness of fibrocystic breast condition among healthcare professionals and the general population, development of advanced techniques and the rise in treatment option. For instance, in 2019, according to CDC, An estimated 287,500 new cases of invasive breast cancer were diagnosed in women.

Some of the major players operating in the market include Pfizer Inc, AstraZeneca, DMS Group, Bayer AG, Siemens Healthcare Private Limited, Hologic, Inc., FUJIFILM Healthcare, Allengers, BMI Biomedical International, GE HealthCare.

1MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Fibrocystic Breast Condition Market
2.2.Research Methodology of the Fibrocystic Breast Condition Market
2.4.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE FIBROCYSTIC BREAST CONDITION MARKET

6GLOBAL FIBROCYSTIC BREAST CONDITION MARKET REVENUE, 2020-2030F

7MARKET INSIGHTS BY DIAGNOSIS

7.1.Mammogram
7.2.Ultrasound
7.3.Clinical Breast Exam
7.4.Other

8MARKET INSIGHTS BY TREATMENT

8.1.Medication
8.2.Oral Contraceptives
8.3.Fine-Needle Aspiration
8.4.Others

9MARKET INSIGHTS BY END-USERS

9.1.Hospital
9.2.Clinic
9.3.Others

10MARKET INSIGHTS BY REGION

10.1NORTH AMERICA FIBROCYSTIC BREAST CONDITION MARKET
- 10.1.1.U.S.
- 10.1.2.Canada
- 10.1.3.Rest of North America
10.2EUROPE FIBROCYSTIC BREAST CONDITION MARKET
- 10.2.1.Germany
- 10.2.2.U.K.
- 10.2.3.France
- 10.2.4.Italy
- 10.2.5.Spain
- 10.2.6.Rest of Europe
10.3ASIA PACIFIC FIBROCYSTIC BREAST CONDITION MARKET
- 10.3.1.China
- 10.3.2.Japan
- 10.3.3.India
- 10.3.4.Rest of Asia-Pacific
10.4REST OF THE WORLD FIBROCYSTIC BREAST CONDITION MARKET